VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016 at 10:00 AM ET. The event is being held at the Sofitel New York Hotel in New York, NY.
During the presentation, Jeff Baxter, VBI’s President and CEO, will provide an overview of VBI and its platform technologies, and will summarize recent developments in the company’s pipeline of vaccine candidates.At the time of the presentation, a live audio webcast will be available at: http://wsw.com/webcast/ladenburg2/vbiv
VBI recommends registering for the webcast at least ten minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived for 90 days following the event.
For additional information, or to schedule a one-on-one meeting with VBI management, please contact email@example.com.
- Event: Ladenburg Thalmann Healthcare Conference
- Date: Tuesday, September 27, 2016
- Location: Sofitel New York Hotel in New York, NY
- Time: 10:00 AM ET
- Event Website: http://bit.ly/ladenburg-2016
- Webcast: http://wsw.com/webcast/ladenburg2/vbiv
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
(617) 830-3031 x124
VBI Investor Contact
Director, Corporate Development and Investor Relations
(617) 830-3031 x128